Skip to content
Menu

TG Therapeutics, Inc. TGTX

Full chart Compare
Set alert

Price alert · TGTX

All alert types
64.51 USD -0.05 (-0.08%)

Regular-session close

64.08 -0.43 -0.67%

Pre-market · Nov 16, 8:13 AM ET

63.38 Day range 64.96
26.76 52-week range 68.03
YTD
+116.40%
1 year
+108.37%
Market cap
9.75B
Revenue (ttm)
897.76M
Profit margin
11.81%
EPS (ttm)
0.67
Shares out
151.15M
P/E ratio
96.28
Forward P/E
24.39
YTD return
+116.40%
1-year return
+108.37%
Volume
1.10M
Avg volume
1.90M
Open
64.40
Previous close
64.56
Day's range
63.38 – 64.96
52-week range
26.76 – 68.03
Beta
1.81
Analysts
Buy
Price target
77.50 (+20.1%)
Earnings date
Feb 25, 2027

5D +6.28 (+10.78%)

556065MonTueWedThuFri64.51

Key statistics

Enterprise value
9.29B
PEG ratio
1.61
Price / sales
10.86
Price / book
15.80
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
60.70%
Free cash flow
85.52M
Total cash
504.67M
Total debt
754.37M
Return on equity
17.99%
Short % of float
27.66%
50-day average
56.54
200-day average
45.21

Fundamental scorecard

13 of 25 checks passed on TGTX’s reported financials

Value: 2/5ValueGrowth: 4/5GrowthProfitability: 4/5ProfitabilityFinancial health: 3/5HealthDividend: 0/5Dividend

13of 25 checks passed

  • Value 2 of 5
  • Growth 4 of 5
  • Profitability 4 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TGTX Revenue — quarterly 259.94M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
TGTX Net income — quarterly 55.46M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
TGTX EPS — quarterly 0.39
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

TGTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20260.56———
Nov 9, 2026Sep 30, 20260.35930.35-0.01-2.59%
Aug 3, 2026Jun 30, 20260.30570.05-0.26-83.64%
May 6, 2026Mar 31, 20260.230.14-0.09-39.13%
Feb 26, 2026Dec 31, 20250.350.14-0.21-60.00%
Nov 3, 2025Sep 30, 20250.242.43+2.19+912.50%

Upgrades / downgrades

TGTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026Evercore ISI GroupmainOutperformOutperform
Sep 1, 2026HC Wainwright & Co.reitBuyBuy
Aug 7, 2026JP MorganmainOverweightOverweight
Jul 27, 2026B. Riley SecuritiesmainBuyBuy
Jul 13, 2026HC Wainwright & Co.mainBuyBuy
Jul 7, 2026B of A SecuritiesmainUnderperformUnderperform

About TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TGTX — it syncs with the Stock Master app.

Insider holders

TGTX insider holders
InsiderRelationLatest transactionDateShares held
CHARNEY LAURENCE NEILDirectorSaleSep 9, 2026168,640
ECHELARD YANNDirectorSaleNov 23, 2025223,816
HOBERMAN KENNETHDirectorStock Award(Grant)Jun 11, 2025279,653
HUME DANIELDirectorStock Award(Grant)Jun 11, 2025192,748
LONIAL SAGARDirectorSaleSep 10, 202594,061
POWER SEAN AChief Financial OfficerStock Award(Grant)Jan 7, 2026798,111

Institution ownership

TGTX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.14.59%22,050,0451.42BJun 29, 2026
State Street Corporation5.62%8,488,874547.62MSep 29, 2026
Vanguard Portfolio Management LLC5.27%7,963,266513.71MJun 29, 2026
Vanguard Capital Management LLC4.07%6,149,403396.70MJun 29, 2026
Geode Capital Management, LLC2.45%3,703,676238.92MSep 29, 2026
Shaw D.E. & Co., Inc.2.25%3,400,808219.39MJun 29, 2026

Fund ownership

TGTX fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.59%8,449,942545.11MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.90%4,377,027282.36MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.49%3,765,888242.94MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.09%3,160,785203.90MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.79%2,703,952174.43MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.20%1,820,899117.47MJun 29, 2026